半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起

格隆汇07-15

7月15日，A股创新药板块延续强势，再度掀起涨停潮。截至发稿，博瑞医药、迪哲医药、睿智医药20CM涨停，哈药股份、海南海药、众生药业、昂利康、昭衍新药、海思科等十余股封板。板块自6月底以来累计涨近18%。港股创新药板块同样火力全开。康方生物、信达生物涨超9%，康诺亚、药明合联、三生制药、亚盛医药、荣昌生物等集体拉升。BD交易持续火热创新药板块近期持续爆发，最直接的催化剂是BD交易的密集落地。7月...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2651879434?lang=zh_CN&edition=full","thumbnail":"https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989","is_english":false,"pubTime":"2026-07-15 13:50","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2651879434","market":"sh","top_or_hot":-1,"title":"半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起","media":"格隆汇","content":"<div>\n<p>7月15日，A股创新药板块延续强势，再度掀起涨停潮。截至发稿，博瑞医药、迪哲医药、睿智医药20CM涨停，哈药股份、海南海药、众生药业、昂利康、昭衍新药、海思科等十余股封板。板块自6月底以来累计涨近18%。港股创新药板块同样火力全开。康方生物、信达生物涨超9%，康诺亚、药明合联、三生制药、亚盛医药、荣昌生物等集体拉升。BD交易持续火热创新药板块近期持续爆发，最直接的催化剂是BD交易的密集落地。7月...</p>\n\n<a href=\"https://www.gelonghui.com/p/5584162\">网页链接</a>\n\n</div>\n","source":"gelonghui_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n半年BD狂飙千亿、龙头预增13倍！创新药涨停潮再起\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-15 13:50 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/5584162><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月15日，A股创新药板块延续强势，再度掀起涨停潮。截至发稿，博瑞医药、迪哲医药、睿智医药20CM涨停，哈药股份、海南海药、众生药业、昂利康、昭衍新药、海思科等十余股封板。板块自6月底以来累计涨近18%。港股创新药板块同样火力全开。康方生物、信达生物涨超9%，康诺亚、药明合联、三生制药、亚盛医药、荣昌生物等集体拉升。BD交易持续火热创新药板块近期持续爆发，最直接的催化剂是BD交易的密集落地。7月...</p>\n\n<a href=\"https://www.gelonghui.com/p/5584162\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"https://www.gelonghui.com/p/5584162","article_id":"2651879434","we_media_id":null,"thumbnails":["https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651879434","pubTimestamp":1784094601,"columns":[],"sourceInfo":{"source_id":"gelonghui_highlight","name":"格隆汇"},"weMediaInfo":null,"summary":"政策密集加码","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","300149":"睿智医药","600664":"哈药股份","688192":"迪哲医药-U","BK0012":"证金概念","BK0077":"质押式回购","06978":"永泰生物-B","BK0028":"国家队","BK1161":"生物科技","BK0060":"抗癌","BK0070":"员工持股","BK1574":"生物医药B类股","BK0239":"医药制造","BK0216":"研究试验","000566":"海南海药","MEDX":"HORIZON KINETICS MEDICAL ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BD":"Russell Investments Core Plus Bond ETF","BK0146":"智慧医疗","002317":"众生药业","002940":"昂利康","BK0188":"融资融券"},"translate_title":"In half a year, BD soared by 100 billion, and the leader increased by 13 times! The daily limit tide of innovative drugs resumes","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"300149":0.9,"600664":0.9,"688192":0.9,"002940":0.9,"06978":1.5,"MEDX":1.5,"002317":0.9,"BD":1.5,"IBBQ":1.5,"000566":0.9},"content_text":"7月15日，A股创新药板块延续强势，再度掀起涨停潮。截至发稿，博瑞医药、迪哲医药、睿智医药20CM涨停，哈药股份、海南海药、众生药业、昂利康、昭衍新药、海思科等十余股封板。板块自6月底以来累计涨近18%。港股创新药板块同样火力全开。康方生物、信达生物涨超9%，康诺亚、药明合联、三生制药、亚盛医药、荣昌生物等集体拉升。BD交易持续火热创新药板块近期持续爆发，最直接的催化剂是BD交易的密集落地。7月14日，迪哲医药一纸公告点燃市场。公司与阿斯利康签署许可协议，授予后者舒沃哲的全球独家开发与商业化权利。仅首付款就入账6亿美元，后续临床开发和销售里程碑款项最高分别达4亿美元和5亿美元，外加全球销售额的阶梯式特许权使用费。就在两周前，石药集团已与阿斯利康达成战略研发合作，围绕小核酸候选药物展开。协议包括3000万美元首付款，最高5.4亿美元潜在研发里程碑付款和最高12亿美元潜在销售里程碑付款，另有基于年净销售额的个位数销售提成。BD交易的火热并非个别案例。国家药监局最新统计显示，今年上半年，国内创新药对外授权共81笔，交易总额约1100亿美元，已达2025年全年总额的80%。业内普遍预计，2026年全年BD交易金额有望再创新高。业绩端同样在验证行业景气度。昭衍新药上半年净利润预计6亿至9亿元，同比暴增884.9%至1377.4%，主要受益于生物资产市场价格上涨及自身增值。翰宇药业预计上半年营收6.8亿至7亿元，同比增长23.76%至27.4%，净利润增速达54.67%至68.42%。康龙化成则受全球化布局深化和新签订单增长超30%的推动，特别是小分子CDMO新签订单同比增超50%，上半年净利润预计7.29亿至7.72亿元，同比增长4%至10%。海思科则预计上半年净利润7.9亿至8.7亿元，同比增幅高达513%至575%，创新药国内销售放量与对外授权首付款入账共同驱动了这轮爆发。政策利好密集发布除了BD交易和业绩利好催化，创新药行业还迎来政策层面的支持。《国民健康\"十五五\"规划》日前印发，明确全链条支持创新药和医疗器械发展，覆盖审评审批优化、临床综合评价健全、临床使用支持等关键环节。国家药监局同步就细胞与基因治疗药品审评审批优化公开征求意见，明确鼓励在中国开展全球同步研发和国际多中心临床试验，符合条件的相关药品可纳入30日审评审批快速通道，进一步提升临床研发效率。与此同时，此前落地的《全链条支持创新药发展实施方案》和2026版基药目录首次纳入4款国产1类创新药，几项政策正在形成合力，为创新药行业发展注入新的动力。东方证券指出，基本药品目录本质上是国家层面为纳入的创新药贴上“基本必需”标签，有望加速其在国内市场放量。一方面，纳入基本药品目录的创新药在参加医保药品准入、医保药品支付管理等方面具备政策协同作用；另一方面，2026版基药目录新增的多数创新药已通过国家医保谈判，纳入目录可加速其在基层医疗机构的配备使用。展望下半年，招商证券认为，调整后的医药创新景气度不变、底部价值明显、资金面较好，看好：全球临床数据优势、出海与商业化兑现能力强的创新药企业，订单修复与结构升级兑现的CXO与上游产业链，同时关注海外放量与科技属性较强的医疗器械，经营向好、重启扩张的药房，低位有变化的个股。兴业证券认为，“创新+国际化”仍为2026年医药核心主线。创新药方面，中国创新药全球竞争力持续加强，政策支持与商业化盈利兑现逻辑不变；当前BD出海仍是企业拓展全球市场的重要方式，Co-Co模式增多体现竞争力与话语权提升；在海外药企专利悬崖压力、国内政策鼓励创新及首发价格机制优化背景下，出海高景气有望延续，板块正由“估值驱动”转向“业绩+全球化兑现驱动”，后续海外三期、上市及商业化分成将成为已BD品种重要催化。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651879434","isCrawlerRequest":true}